APASL-话题@MedSci - williamhill asia

#APASL#

28篇内容 | 1409人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1598431, encodeId=a2d4159843115, content=<a href='/topic/show?id=a8952625e5' target=_blank style='color:#2F92EE;'>#APASL#</a>, objectTitle=APASL 2014：乙肝的治疗终点及其实现方法, objectType=article, longId=32144, objectId=87f83214456, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=87f83214456, replyNumber=0, likeNumber=59, createdTime=2014-03-21, rootId=0, userName=tongyongming, userId=b18118584502, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=87f83214456, moduleTitle=APASL 2014：乙肝的治疗终点及其实现方法, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=87f83214456)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1598430, encodeId=dc0c1598430c9, content=<a href='/topic/show?id=a8952625e5' target=_blank style='color:#2F92EE;'>#APASL#</a>, objectTitle=北京大学人民医院魏来教授当选亚太肝病学会（APASL）执行委员, objectType=article, longId=21994, objectId=beac21994a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=beac21994a7, replyNumber=0, likeNumber=58, createdTime=2013-07-26, rootId=0, userName=tongyongming, userId=b18118584502, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=beac21994a7, moduleTitle=北京大学人民医院魏来教授当选亚太肝病学会（APASL）执行委员, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=beac21994a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1598429, encodeId=9b7915984292a, content=<a href='/topic/show?id=a8952625e5' target=_blank style='color:#2F92EE;'>#APASL#</a>, objectTitle=APASL 2013：恩替卡韦长期抗病毒治疗降低HCC风险, objectType=article, longId=21705, objectId=738021e0540, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=738021e0540, replyNumber=0, likeNumber=63, createdTime=2013-07-21, rootId=0, userName=tongyongming, userId=b18118584502, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=738021e0540, moduleTitle=APASL 2013：恩替卡韦长期抗病毒治疗降低HCC风险, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=738021e0540)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1598428, encodeId=a8ee1598428ea, content=<a href='/topic/show?id=a8952625e5' target=_blank style='color:#2F92EE;'>#APASL#</a>, objectTitle=2013亚太肝脏研究学会（APASL）主席推荐的重点报告, objectType=article, longId=21330, objectId=60392133007, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=60392133007, replyNumber=0, likeNumber=60, createdTime=2013-07-15, rootId=0, userName=tongyongming, userId=b18118584502, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=60392133007, moduleTitle=2013亚太肝脏研究学会（APASL）主席推荐的重点报告, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=60392133007)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1598427, encodeId=545a159842e49, content=<a href='/topic/show?id=a8952625e5' target=_blank style='color:#2F92EE;'>#APASL#</a>, objectTitle=新版APASL《丙型肝炎病毒感染共识和治疗程序》发布, objectType=article, longId=4362, objectId=b6b6436291, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6b6436291, replyNumber=0, likeNumber=46, createdTime=2012-03-24, rootId=0, userName=tongyongming, userId=b18118584502, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6b6436291, moduleTitle=新版APASL《丙型肝炎病毒感染共识和治疗程序》发布, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=b6b6436291)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1598426, encodeId=eaf3159842653, content=<a href='/topic/show?id=a8952625e5' target=_blank style='color:#2F92EE;'>#APASL#</a>, objectTitle=陈成伟：CHB初治药物选择 [APASL 2012], objectType=article, longId=4292, objectId=19864292ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19864292ab, replyNumber=0, likeNumber=50, createdTime=2012-03-12, rootId=0, userName=tongyongming, userId=b18118584502, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19864292ab, moduleTitle=陈成伟：CHB初治药物选择 [APASL 2012], moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=19864292ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1598425, encodeId=284015984250f, content=<a href='/topic/show?id=a8952625e5' target=_blank style='color:#2F92EE;'>#APASL#</a>, objectTitle=牛俊奇：从2012 新版APASL威廉亚洲博彩公司看替比夫定的临床应用, objectType=article, longId=4220, objectId=dbab4220d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbab4220d4, replyNumber=0, likeNumber=59, createdTime=2012-03-06, rootId=0, userName=tongyongming, userId=b18118584502, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbab4220d4, moduleTitle=牛俊奇：从2012 新版APASL威廉亚洲博彩公司看替比夫定的临床应用, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=dbab4220d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1598424, encodeId=7e65159842422, content=<a href='/topic/show?id=a8952625e5' target=_blank style='color:#2F92EE;'>#APASL#</a>, objectTitle=2012年APASL《亚太地区慢性乙型肝炎管理共识》, objectType=article, longId=4160, objectId=15e2416008, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15e2416008, replyNumber=0, likeNumber=60, createdTime=2012-02-29, rootId=0, userName=tongyongming, userId=b18118584502, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15e2416008, moduleTitle=2012年APASL《亚太地区慢性乙型肝炎管理共识》, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=15e2416008)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1598423, encodeId=3bf7159842303, content=<a href='/topic/show?id=a8952625e5' target=_blank style='color:#2F92EE;'>#APASL#</a>, objectTitle=庄辉：2012版APASL慢性乙型肝炎诊疗威廉亚洲博彩公司更新要点, objectType=article, longId=4159, objectId=82184159b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82184159b7, replyNumber=0, likeNumber=48, createdTime=2012-02-29, rootId=0, userName=tongyongming, userId=b18118584502, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82184159b7, moduleTitle=庄辉：2012版APASL慢性乙型肝炎诊疗威廉亚洲博彩公司更新要点, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=82184159b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1598422, encodeId=331b1598422b8, content=<a href='/topic/show?id=a8952625e5' target=_blank style='color:#2F92EE;'>#APASL#</a>, objectTitle=APASL发布《亚太地区慢性乙型肝炎治疗共识（2012更新版）》, objectType=article, longId=4137, objectId=a796413e78, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a796413e78, replyNumber=0, likeNumber=46, createdTime=2012-02-26, rootId=0, userName=tongyongming, userId=b18118584502, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a796413e78, moduleTitle=APASL发布《亚太地区慢性乙型肝炎治疗共识（2012更新版）》, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=a796413e78)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1598421, encodeId=6dfa15984215b, content=<a href='/topic/show?id=a8952625e5' target=_blank style='color:#2F92EE;'>#APASL#</a>, objectTitle=2012 APASL会议日程, objectType=article, longId=4073, objectId=c92340e325, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c92340e325, replyNumber=0, likeNumber=64, createdTime=2012-02-19, rootId=0, userName=tongyongming, userId=b18118584502, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c92340e325, moduleTitle=2012 APASL会议日程, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=c92340e325)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1598420, encodeId=95071598420de, content=<a href='/topic/show?id=a8952625e5' target=_blank style='color:#2F92EE;'>#APASL#</a>, objectTitle=APASL将发乙丙肝新威廉亚洲博彩公司 , objectType=article, longId=4071, objectId=b2f740e1a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b2f740e1a7, replyNumber=0, likeNumber=55, createdTime=2012-02-19, rootId=0, userName=tongyongming, userId=b18118584502, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b2f740e1a7, moduleTitle=APASL将发乙丙肝新威廉亚洲博彩公司 , moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=b2f740e1a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1598419, encodeId=ace01598419ed, content=<a href='/topic/show?id=a8952625e5' target=_blank style='color:#2F92EE;'>#APASL#</a>, objectTitle=APASL慢性乙型肝炎管理威廉亚洲博彩公司 (2008版), objectType=article, longId=2059, objectId=77a02059a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=77a02059a1, replyNumber=0, likeNumber=51, createdTime=2010-08-25, rootId=0, userName=tongyongming, userId=b18118584502, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=77a02059a1, moduleTitle=APASL慢性乙型肝炎管理威廉亚洲博彩公司 (2008版), moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=77a02059a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] williamhill asia 话题小助手

APASL

2020-05-29

tongyongming (审核中...)

前往app查看评论内容

#APASL#

APASL 2014：乙肝的治疗终点及其实现方法

2014-03-21

tongyongming (审核中...)

前往app查看评论内容

#APASL#

北京大学人民医院魏来教授当选亚太肝病学会（APASL）执行委员

2013-07-26

tongyongming (审核中...)

前往app查看评论内容

#APASL#

APASL 2013：恩替卡韦长期抗病毒治疗降低HCC风险

2013-07-21

tongyongming (审核中...)

前往app查看评论内容

#APASL#

2013亚太肝脏研究学会（APASL）主席推荐的重点报告

2013-07-15

tongyongming (审核中...)

前往app查看评论内容

#APASL#

新版APASL《丙型肝炎病毒感染共识和治疗程序》发布

2012-03-24

tongyongming (审核中...)

前往app查看评论内容

#APASL#

陈成伟：CHB初治药物选择 [APASL 2012]

2012-03-12

tongyongming (审核中...)

前往app查看评论内容

#APASL#

牛俊奇：从2012 新版APASL威廉亚洲博彩公司看替比夫定的临床应用

2012-03-06

tongyongming (审核中...)

前往app查看评论内容

#APASL#

2012年APASL《亚太地区慢性乙型肝炎管理共识》

2012-02-29

tongyongming (审核中...)

前往app查看评论内容

#APASL#

庄辉：2012版APASL慢性乙型肝炎诊疗威廉亚洲博彩公司更新要点

2012-02-29

tongyongming (审核中...)

前往app查看评论内容

#APASL#

APASL发布《亚太地区慢性乙型肝炎治疗共识（2012更新版）》

2012-02-26

tongyongming (审核中...)

前往app查看评论内容

#APASL#

2012 APASL会议日程

2012-02-19

tongyongming (审核中...)

前往app查看评论内容

#APASL#

APASL将发乙丙肝新威廉亚洲博彩公司

2012-02-19

tongyongming (审核中...)

前往app查看评论内容

#APASL#

APASL慢性乙型肝炎管理威廉亚洲博彩公司 (2008版)

2010-08-25

科室
- - 订阅+
  - 更多科室
工具
服务